Selenium Blood Test: What It Actually Measures and Why It Matters

What the Selenium Blood Test Actually Measures

The test quantifies total selenium concentration in serum or plasma, expressed in mcg/L or ng/mL. It reflects circulating selenium bound to selenoprotein P (SELENOP), glutathione peroxidase 3 (GPx3), and albumin. SELENOP alone accounts for roughly 50% to 60% of plasma selenium in adequately nourished individuals [1].

A single serum measurement captures your selenium status at the time of the draw. It does not directly measure intracellular selenium stores or selenoprotein activity, though serum levels correlate well with functional selenoprotein expression when concentrations fall between 70 and 150 mcg/L [2]. Whole blood selenium testing is available but less commonly ordered; it reflects longer-term intake because red blood cells incorporate selenium during erythropoiesis and retain it for the cell's 120-day lifespan.

The biological role of selenium centers on its incorporation into selenocysteine, often called the 21st amino acid. Selenocysteine is co-translationally inserted into at least 25 human selenoproteins, each with distinct functions [3]. Three families matter most clinically: the glutathione peroxidases (antioxidant defense), the iodothyronine deiodinases (thyroid hormone activation), and the thioredoxin reductases (redox regulation and DNA repair). Without adequate selenium, these enzyme systems lose catalytic efficiency in a predictable, dose-dependent pattern.

Normal Selenium Ranges and How Labs Report Them

Most U.S. reference laboratories report a serum selenium range of 70 to 150 mcg/L. This range is not arbitrary. It is derived from population-based studies linking serum selenium to maximal GPx3 activity, which plateaus near 90 to 100 mcg/L, and to saturated SELENOP concentrations, which plateau around 110 to 125 mcg/L [4].

The distinction between "normal" and "optimal" matters here. A serum selenium of 72 mcg/L falls within the reference range, but GPx3 activity at that level may be only 60% to 70% of maximum. The 2021 European Thyroid Association (ETA) guidelines note that "selenium supplementation to optimize selenoprotein activity requires serum concentrations of at least 100 mcg/L" [5]. For thyroid patients specifically, many endocrinologists target 100 to 130 mcg/L.

Geographic variation is significant. Selenium enters the food chain through soil. Populations in selenium-poor regions (parts of China, Finland before soil fortification, New Zealand) show markedly lower serum levels. A 2017 Lancet systematic review (N=142 studies) estimated that approximately 500 million to 1 billion people worldwide have insufficient selenium intake [6]. In the United States, mean serum selenium is approximately 125 mcg/L due to selenium-rich agricultural soils in the Great Plains, but individual variation spans a wide range depending on diet, geography, and gastrointestinal absorption capacity.

What Low Selenium Means Clinically

Serum selenium below 70 mcg/L signals deficiency. Values between 70 and 85 mcg/L represent a suboptimal zone where selenoprotein function is measurably impaired but overt clinical disease has not yet developed.

Severe selenium deficiency (below 30 mcg/L) is associated with two named conditions. Keshan disease, a cardiomyopathy first described in Keshan County, China, results from combined selenium deficiency and coxsackievirus B infection [7]. Kashin-Beck disease presents as an osteoarthropathy affecting cartilage and growth plates in children and adolescents. Both are rare in developed nations but remain endemic in parts of rural China and Tibet.

More commonly encountered in U.S. clinical practice: moderate deficiency (40 to 70 mcg/L) contributes to impaired thyroid hormone metabolism. The type 2 deiodinase (DIO2) that converts thyroxine (T4) to the active triiodothyronine (T3) requires selenocysteine at its active site. A prospective cohort study published in the Journal of Clinical Endocrinology & Metabolism (N=1,900) found that participants in the lowest quartile of serum selenium had a 1.62-fold higher risk of subclinical hypothyroidism compared to the highest quartile (95% CI: 1.12 to 2.34) [8].

Other clinical associations with low selenium include:

• Reduced glutathione peroxidase activity, leading to increased oxidative stress markers (F2-isoprostanes, malondialdehyde)
• Impaired immune function, specifically reduced natural killer cell activity and impaired T-cell proliferation [9]
• Increased susceptibility to viral mutations, as demonstrated in studies showing that selenium-deficient hosts allow benign coxsackievirus strains to mutate toward virulence [7]
• Male subfertility, because selenoprotein GPx4 (phospholipid hydroperoxide glutathione peroxidase) is a structural component of the sperm midpiece

Risk factors for low selenium include gastric bypass surgery, chronic inflammatory bowel disease, long-term parenteral nutrition without selenium supplementation, and celiac disease. Patients on dialysis also lose selenium through the dialysis membrane.

What High Selenium Means: Selenosis and Toxicity

Serum selenium above 150 mcg/L warrants clinical attention. Values above 400 mcg/L indicate frank selenosis. The tolerable upper intake level set by the Institute of Medicine is 400 mcg/day from all sources, and chronic intake above this threshold produces a recognizable toxicity syndrome [10].

Early signs of excess selenium include garlic-like breath odor (from dimethyl selenide exhalation), brittle nails with horizontal streaking, and hair loss. These are reversible with dose reduction. Progression to severe selenosis causes peripheral neuropathy, fatigue, irritability, and gastrointestinal disturbance.

The Nutritional Prevention of Cancer (NPC) trial, originally designed to test selenium supplementation (200 mcg/day as selenized yeast) against skin cancer recurrence, unexpectedly revealed an increased risk of type 2 diabetes in the supplementation group. A post-hoc analysis (N=1,202) found a hazard ratio of 1.55 (95% CI: 1.03 to 2.33) for type 2 diabetes among participants with baseline plasma selenium above 121.6 ng/mL who received additional supplementation [11]. The SELECT trial (N=35,533) later confirmed that 200 mcg/day of selenomethionine did not reduce prostate cancer risk and suggested a non-significant trend toward increased type 2 diabetes [12].

These findings reshaped clinical guidance. The American Association of Clinical Endocrinology (AACE) now recommends against routine selenium supplementation in individuals with adequate baseline levels, stating that "supplementation in selenium-replete populations may carry metabolic risk without demonstrable benefit" [13].

How to Raise Low Selenium Levels

Correcting deficiency involves dietary modification, supplementation, or both, depending on the severity of depletion and the underlying cause.

Dietary sources provide selenium in organic forms (selenomethionine and selenocysteine) that have high bioavailability, typically 80% to 90% absorption. Brazil nuts are the most concentrated food source, containing approximately 68 to 91 mcg per nut depending on soil conditions [14]. Two Brazil nuts daily can raise serum selenium by 30 to 65 mcg/L over 12 weeks based on a randomized trial in New Zealand (N=59) that documented a 64.2% increase in GPx activity from baseline [15].

Other selenium-rich foods include yellowfin tuna (92 mcg per 3 oz), halibut (47 mcg per 3 oz), sardines (45 mcg per 3 oz), turkey (31 mcg per 3 oz), and eggs (15 mcg per large egg) [14].

When supplementation is indicated, two forms predominate:

• Selenomethionine: An organic form that incorporates nonspecifically into body proteins in place of methionine, creating a tissue reservoir. This is the form used in the NPC and SELECT trials.
• Sodium selenite: An inorganic form that is directly metabolized to selenide for selenoprotein synthesis without nonspecific tissue storage. Some clinicians prefer this form to avoid excessive accumulation.

Standard repletion dosing ranges from 100 to 200 mcg/day for 8 to 12 weeks, with repeat serum testing to confirm target attainment. Dr. Margaret Rayman, Professor of Nutritional Medicine at the University of Surrey and a leading selenium researcher, has noted that "the window between selenium deficiency and toxicity is narrower than for most trace elements, making monitoring during supplementation particularly important" [16].

For patients with malabsorption syndromes, parenteral selenium (as selenious acid, 60 to 100 mcg/day IV) is available and is a standard component of trace element formulations in total parenteral nutrition protocols per ASPEN guidelines [17].

Selenium and Thyroid Function: The Clinical Connection

The thyroid gland contains more selenium per gram of tissue than any other organ. This concentration is not incidental. Both the activation and inactivation of thyroid hormones depend on selenium-containing deiodinases.

Three deiodinases govern peripheral thyroid hormone metabolism. DIO1 and DIO2 convert T4 to the metabolically active T3 (outer ring deiodination). DIO3 converts T4 to the inactive reverse T3 (rT3) and degrades T3 to T2 (inner ring deiodination). All three are selenoproteins [18].

The clinical significance is most apparent in autoimmune thyroid disease. A 2002 randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism by Gärtner et al. (N=70) found that supplementation with 200 mcg/day of sodium selenite for 3 months reduced thyroid peroxidase antibody (TPO-Ab) titers by 36.4% compared to a 12% increase in the placebo group (P<0.01) [19]. Multiple subsequent trials have replicated this finding with varying effect sizes.

The 2021 ETA guidelines recommend considering selenium supplementation (200 mcg/day for 6 months) specifically in patients with mild Graves' orbitopathy, citing the EUGOGO trial (N=159) that showed improvement in quality of life scores and a slowed progression rate in the selenium group compared to placebo [5]. The guidelines stop short of blanket recommendations for Hashimoto's thyroiditis, noting that "while TPO-Ab reduction is consistent across trials, evidence for clinically meaningful changes in thyroid function or patient-relevant outcomes remains limited."

For patients presenting with both suboptimal selenium and thyroid dysfunction, checking selenium before initiating or adjusting levothyroxine can provide useful context. A T4-to-T3 conversion problem driven by selenium insufficiency will not respond to dose escalation of levothyroxine alone.

Selenium as an Antioxidant Biomarker

Selenium's antioxidant role operates through the glutathione peroxidase family. GPx1 (cytosolic), GPx2 (gastrointestinal), GPx3 (extracellular/plasma), and GPx4 (phospholipid-associated) all use selenium at their catalytic sites to reduce hydrogen peroxide and lipid hydroperoxides to water and corresponding alcohols [3].

GPx3, the plasma isoform measured indirectly through serum selenium testing, serves as a circulating antioxidant that protects lipoproteins from oxidative modification. A nested case-control study within the EPIC-Heidelberg cohort (N=474 cases, 474 controls) found that participants in the lowest quartile of serum selenium had a statistically significant increase in colorectal cancer risk (OR 1.39, 95% CI: 1.01 to 1.92) after adjustment for confounders [20].

The thioredoxin reductase system, the other major selenoprotein antioxidant pathway, regenerates oxidized thioredoxin, which in turn reduces oxidized proteins and regulates redox-sensitive transcription factors including NF-kB and AP-1. This pathway links selenium status to inflammatory signaling at the molecular level.

Clinicians ordering selenium as part of an antioxidant or inflammatory workup should consider pairing it with plasma glutathione, 8-OHdG (a DNA oxidation marker), or F2-isoprostanes for a more complete picture of oxidative stress burden.

Who Should Get Tested and How Often

Selenium testing is not part of standard wellness panels. It is a targeted test ordered when clinical suspicion or risk factors exist. Appropriate indications include:

• Unexplained thyroid dysfunction not responsive to standard levothyroxine dosing, particularly impaired T4-to-T3 conversion
• Autoimmune thyroid disease (Hashimoto's or Graves'), especially if considering selenium supplementation as adjunctive therapy
• Post-bariatric surgery monitoring (recommended by ASMBS at 6-month intervals for the first 2 years)
• Chronic malabsorption from celiac disease, Crohn's disease, short bowel syndrome, or chronic pancreatitis
• Long-term parenteral nutrition (quarterly monitoring per ASPEN guidelines) [17]
• Unexplained cardiomyopathy in patients with risk factors for nutritional deficiency
• Male infertility workup when semen analysis shows abnormal morphology or motility
• Patients taking high-dose selenium supplements, to screen for excess

Recheck intervals depend on the clinical scenario. For repletion monitoring, a follow-up draw 8 to 12 weeks after initiating supplementation is standard. For maintenance monitoring in bariatric or malabsorption patients, every 6 to 12 months is typical.

The test itself requires no special preparation. Fasting is not required. Hemolyzed samples can falsely raise results because red blood cells contain selenium-dependent GPx1, so a clean, non-hemolyzed specimen is important for accurate results.

Interactions with Other Nutrients and Medications

Selenium does not function in isolation. Its metabolism intersects with iodine, zinc, iron, and vitamin E in clinically relevant ways.

Selenium and iodine have a bidirectional relationship in thyroid physiology. Selenium deficiency combined with iodine deficiency worsens hypothyroidism more than either deficiency alone. Critically, correcting selenium deficiency before correcting iodine deficiency in severely iodine-depleted populations can paradoxically worsen hypothyroidism by increasing DIO2-mediated T4 degradation [18]. The WHO recommends addressing iodine status first in dual-deficiency settings.

Selenium and vitamin E have complementary antioxidant roles. Vitamin E (alpha-tocopherol) scavenges lipid peroxyl radicals in cell membranes, while GPx4 reduces the resulting lipid hydroperoxides. Animal models demonstrate that vitamin E deficiency accelerates the clinical manifestations of selenium deficiency and vice versa [3].

Drug interactions are less well characterized, but proton pump inhibitors (PPIs) may reduce selenium absorption by increasing gastric pH, and cisplatin-based chemotherapy regimens are associated with selenium depletion. Patients on long-term PPI therapy who present with suboptimal selenium should have dietary intake assessed before attributing the finding to medication effects alone.

Serum selenium of 55 mcg/L in a post-Roux-en-Y patient on chronic PPI therapy tells a different clinical story than the same value in a vegan athlete who simply does not eat selenium-rich foods. Context determines the intervention.